MorphoSys Teams Up Again With Novartis For Preclinical Cancer Program
Gets $23m Upfront Fee
The German biotech announced in March that it was terminating the early-stage oncology R&D projects that came with its purchase of Constellation last year and Novartis has snapped up one of them.